Results 1 to 10 of about 140,089 (205)

Apparent Survival Benefit of Postoperative Radioactive Iodine in Lymph Node-Positive Papillary Thyroid Carcinoma: A Negative-Control Analysis for Unmeasured Confounding. [PDF]

open access: yesCancer Med
ABSTRACT Background Observational studies report an overall‐survival advantage for postoperative radioactive iodine (RAI) in lymph node–positive papillary thyroid carcinoma (PTC), but such estimates are vulnerable to confounding by indication and to bias from immortal time and the healthy‐user effect.
Liu T, Qiao J, Mao M, Guo Q, Yang F.
europepmc   +2 more sources

Current Status and Progress of Radioligand Therapy in Advanced Malignant Tumors

open access: yesZhongliu Fangzhi Yanjiu
In 1946, radioactive iodine 131 was first used for the treatment of differentiated thyroid cancer. However, the limitations of early nuclear medicine technology, the lack of specificity, the efficacy of nuclide therapy, and its adverse effects have ...
Dasheng QIU   +3 more
doaj   +1 more source

Theranostics Nuclear Medicine in Prostate Cancer

open access: yesPharmaceuticals
Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases ...
Helena Lima   +7 more
doaj   +1 more source

Predictive factors for metabolic profile alterations following radioactive iodine treatment in hyperthyroidism

open access: yesZaporožskij Medicinskij Žurnal
Radioactive iodine (RAI) therapy is an effective treatment for hyperthyroidism, particularly Graves’ disease and toxic adenoma. Although its efficacy in normalizing thyroid hormone levels is well-established, predictive biomarkers for long-term metabolic
A. E. Mammadova
doaj   +1 more source

Symptom Management Following Radioactive Iodine Treatment in Adults With Thyroid Cancer: Usability Evaluation and Proof-of-Concept Study. [PDF]

open access: yesJMIR Cancer
Carr A   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy